Fluarix Tetra — Competitive Intelligence Brief

Fluarix Tetra (Fluarix Tetra) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine (quadrivalent). Area: Immunology.

phase 3 Inactivated influenza vaccine (quadrivalent) Immunology Biologic

Target snapshot

Fluarix Tetra (Fluarix Tetra) — University of Surrey. Fluarix Tetra is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluarix Tetra TARGET	Fluarix Tetra	University of Surrey	phase 3	Inactivated influenza vaccine (quadrivalent)
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)
FluQuadri	FluQuadri	Centers for Disease Control and Prevention	phase 3	Inactivated influenza vaccine (quadrivalent)
Fluarix Tetra Pre-filled Syringe	Fluarix Tetra Pre-filled Syringe	Il-Yang Pharm. Co., Ltd.	phase 3	Inactivated influenza vaccine (quadrivalent)	Influenza virus surface antigens (hemagglutinin and neuraminidase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine (quadrivalent) class)

1. Aarhus University Hospital · 1 drug in this class
2. Centers for Disease Control and Prevention · 1 drug in this class
3. Il-Yang Pharm. Co., Ltd. · 1 drug in this class
4. University of Surrey · 1 drug in this class